Q-omics provides the consensus-scored CCDC85A profile across patient tissues and cancer cell-line models. CCDC85A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC85A is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, CCDC85A RNA expression shows 18,367 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where CCDC85A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC85A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC85A survival associations across molecular data types. CCDC85A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC85A RNA expression–survival associations across cancer types. High CCDC85A expression shows unfavorable associations in BLCA, MESO and LUSC, but favorable associations in KIRC, LGG and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC85A RNA expression.
This table summarizes CCDC85A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC85A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC85A shows lower tumor expression in THCA, LUAD, LUSC, UCEC and COAD and higher tumor expression in KIRC. The THCA box plot shows higher CCDC85A RNA expression in normal versus tumor tissue (log2 FC = −2.277, t-test p < 0.001).
This table shows molecular features associated with CCDC85A in patient tissues and cancer cell lines. In patient samples, CCDC85A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC85A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
